ADHD medicine consumption in Europe after COVID-19: catch-up or trend change?
Abstract Background Although the COVID-19 pandemic and its implications have been associated with mental health services utilization and medication consumption, there is no longitudinal study on the long-term impact on ADHD medication use trends. Methods This study examines the European ADHD medicat...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-02-01
|
| Series: | BMC Psychiatry |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12888-024-05505-9 |
| _version_ | 1827326605724221440 |
|---|---|
| author | Sophie Gimbach Daniel Vogel Roland Fried Stephen V. Faraone Tobias Banaschewski Jan Buitelaar Manfred Döpfner Richard Ammer |
| author_facet | Sophie Gimbach Daniel Vogel Roland Fried Stephen V. Faraone Tobias Banaschewski Jan Buitelaar Manfred Döpfner Richard Ammer |
| author_sort | Sophie Gimbach |
| collection | DOAJ |
| description | Abstract Background Although the COVID-19 pandemic and its implications have been associated with mental health services utilization and medication consumption, there is no longitudinal study on the long-term impact on ADHD medication use trends. Methods This study examines the European ADHD medication consumption in 2020 to 2022 compared to the predicted consumption assuming the persistence of pre-pandemic trends. Predictions are calculated using Seasonal Autoregressive Integrated Moving Average (SARIMA) models. Results While European ADHD medication sales recorded a drop in 2020, they returned to the predicted level in 2021, even slightly exceeding it. In 2022, we found a clear exceedance of the predicted level by 16.4% on average at country level. Furthermore, the increase in consumption growth in the post-pandemic period (2021–2022) compared to the pre-pandemic period (2014–2019) was significant in 26 of the 28 European countries under consideration. Conclusion There is strong evidence of a trend change in the ADHD medicine consumption growth throughout Europe after the COVID-19 pandemic. |
| first_indexed | 2024-03-07T14:48:01Z |
| format | Article |
| id | doaj.art-cc2f0cd90a6c4bb1a51bf3b2ebe44d8a |
| institution | Directory Open Access Journal |
| issn | 1471-244X |
| language | English |
| last_indexed | 2024-03-07T14:48:01Z |
| publishDate | 2024-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Psychiatry |
| spelling | doaj.art-cc2f0cd90a6c4bb1a51bf3b2ebe44d8a2024-03-05T19:54:01ZengBMCBMC Psychiatry1471-244X2024-02-0124111010.1186/s12888-024-05505-9ADHD medicine consumption in Europe after COVID-19: catch-up or trend change?Sophie Gimbach0Daniel Vogel1Roland Fried2Stephen V. Faraone3Tobias Banaschewski4Jan Buitelaar5Manfred Döpfner6Richard Ammer7Data Science Hub, MEDICE Arzneimittel Pütter GmbH & Co. KGData Science Hub, MEDICE Arzneimittel Pütter GmbH & Co. KGDepartment of Statistics, TU Dortmund UniversityDepartment of Psychiatry, SUNY Upstate Medical UniversityMedical Faculty Mannheim, Central Institute of Mental Health, Heidelberg UniversityDepartment of Cognitive Neuroscience, Radboud University Medical CenterDepartment of Child and Adolescent Psychiatry and Psychotherapy, Medical Faculty, University of CologneData Science Hub, MEDICE Arzneimittel Pütter GmbH & Co. KGAbstract Background Although the COVID-19 pandemic and its implications have been associated with mental health services utilization and medication consumption, there is no longitudinal study on the long-term impact on ADHD medication use trends. Methods This study examines the European ADHD medication consumption in 2020 to 2022 compared to the predicted consumption assuming the persistence of pre-pandemic trends. Predictions are calculated using Seasonal Autoregressive Integrated Moving Average (SARIMA) models. Results While European ADHD medication sales recorded a drop in 2020, they returned to the predicted level in 2021, even slightly exceeding it. In 2022, we found a clear exceedance of the predicted level by 16.4% on average at country level. Furthermore, the increase in consumption growth in the post-pandemic period (2021–2022) compared to the pre-pandemic period (2014–2019) was significant in 26 of the 28 European countries under consideration. Conclusion There is strong evidence of a trend change in the ADHD medicine consumption growth throughout Europe after the COVID-19 pandemic.https://doi.org/10.1186/s12888-024-05505-9ADHDCOVID19PandemicPharmacoepidemiologyTime series forecasting |
| spellingShingle | Sophie Gimbach Daniel Vogel Roland Fried Stephen V. Faraone Tobias Banaschewski Jan Buitelaar Manfred Döpfner Richard Ammer ADHD medicine consumption in Europe after COVID-19: catch-up or trend change? BMC Psychiatry ADHD COVID19 Pandemic Pharmacoepidemiology Time series forecasting |
| title | ADHD medicine consumption in Europe after COVID-19: catch-up or trend change? |
| title_full | ADHD medicine consumption in Europe after COVID-19: catch-up or trend change? |
| title_fullStr | ADHD medicine consumption in Europe after COVID-19: catch-up or trend change? |
| title_full_unstemmed | ADHD medicine consumption in Europe after COVID-19: catch-up or trend change? |
| title_short | ADHD medicine consumption in Europe after COVID-19: catch-up or trend change? |
| title_sort | adhd medicine consumption in europe after covid 19 catch up or trend change |
| topic | ADHD COVID19 Pandemic Pharmacoepidemiology Time series forecasting |
| url | https://doi.org/10.1186/s12888-024-05505-9 |
| work_keys_str_mv | AT sophiegimbach adhdmedicineconsumptionineuropeaftercovid19catchuportrendchange AT danielvogel adhdmedicineconsumptionineuropeaftercovid19catchuportrendchange AT rolandfried adhdmedicineconsumptionineuropeaftercovid19catchuportrendchange AT stephenvfaraone adhdmedicineconsumptionineuropeaftercovid19catchuportrendchange AT tobiasbanaschewski adhdmedicineconsumptionineuropeaftercovid19catchuportrendchange AT janbuitelaar adhdmedicineconsumptionineuropeaftercovid19catchuportrendchange AT manfreddopfner adhdmedicineconsumptionineuropeaftercovid19catchuportrendchange AT richardammer adhdmedicineconsumptionineuropeaftercovid19catchuportrendchange |